# A041702 (NCT03737981)

> Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03737981
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions: Ibrutinib; Obinutuzumab; Observation Activity; Venetoclax
- Enrollment: 465
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on A041702 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=a041702-nct03737981